28412693|t|Feeding Angptl4-/- mice trans fat promotes foam cell formation in mesenteric lymph nodes without leading to ascites
28412693|a|ANGPTL4 regulates plasma triglyceride levels by inhibiting lipoprotein lipase. Inactivation of ANGPTL4 decreases plasma triglycerides and reduces risk of coronary artery disease. Unfortunately, targeting ANGPTL4 for the therapeutic management of dyslipidemia and atherosclerosis is hampered by the observation that mice and monkeys in which ANGPTL4 is inactivated exhibit lipid accumulation in mesenteric lymph nodes. In mice these pathological events exclusively unfold upon feeding a high saturated fatty acid diet and are followed by an ultimately lethal pro-inflammatory response and chylous ascites. Here we show that Angptl4-/- mice fed a diet rich in trans fatty acids develop numerous lipid -filled giant cells in their mesenteric lymph nodes, yet do not have elevated serum amyloid and haptoglobin, do not exhibit ascites, and survive, unlike Angptl4-/- mice fed a saturated fatty acid -rich diet. In RAW264.7 macrophages the saturated fatty acid palmitate markedly increases markers of inflammation and the unfolded protein response, whereas the trans-unsaturated elaidate and the cis-unsaturated oleate have the opposite effect. In conclusion, trans and saturated fatty acids have very distinct biological effects. Furthermore, lipid accumulation in mesenteric lymph nodes is uncoupled from activation of an acute-phase response and chylous ascites, suggesting that ANGPTL4 should not be fully dismissed as target for dyslipidemia.
28412693	0	7	Feeding	T052	C2987508
28412693	8	18	Angptl4-/-	T028	C1423931
28412693	19	23	mice	T015	C0206745
28412693	24	33	trans fat	T109,T168	C1257879
28412693	43	52	foam cell	T025	C0016390
28412693	53	62	formation	T169	C1522492
28412693	66	88	mesenteric lymph nodes	T023	C0229792
28412693	89	96	without	T080	C0332288
28412693	97	104	leading	T169	C0332294
28412693	108	115	ascites	T033	C0003962
28412693	116	123	ANGPTL4	T116,T123	C1438918
28412693	134	140	plasma	T031	C0032105
28412693	141	153	triglyceride	T109,T123	C0041004
28412693	164	174	inhibiting	T052	C3463820
28412693	175	193	lipoprotein lipase	T116,T126	C0023816
28412693	195	207	Inactivation	T045	C0598496
28412693	211	218	ANGPTL4	T116,T123	C1438918
28412693	229	235	plasma	T031	C0032105
28412693	236	249	triglycerides	T109,T123	C0041004
28412693	270	293	coronary artery disease	T047	C0010068
28412693	320	327	ANGPTL4	T116,T123	C1438918
28412693	336	347	therapeutic	T169	C0302350
28412693	348	358	management	T058	C0086388
28412693	362	374	dyslipidemia	T047	C0242339
28412693	379	394	atherosclerosis	T047	C0004153
28412693	431	435	mice	T015	C0025929
28412693	440	447	monkeys	T015	C0026447
28412693	457	464	ANGPTL4	T116,T123	C1438918
28412693	468	479	inactivated	T169	C0544461
28412693	488	506	lipid accumulation	T033	C0333574
28412693	510	532	mesenteric lymph nodes	T023	C0229792
28412693	537	541	mice	T015	C0025929
28412693	548	560	pathological	T169	C1521733
28412693	561	567	events	T051	C0441471
28412693	592	599	feeding	T052	C2987508
28412693	602	627	high saturated fatty acid	T168	C0597423
28412693	628	632	diet	T168	C0012155
28412693	667	673	lethal	T033	C3151529
28412693	674	699	pro-inflammatory response	T046	C1155266
28412693	704	719	chylous ascites	T047	C0008732
28412693	739	749	Angptl4-/-	T028	C1423931
28412693	750	754	mice	T015	C0206745
28412693	755	758	fed	T052	C2987508
28412693	761	765	diet	T168	C0012155
28412693	774	791	trans fatty acids	T109,T168	C1257879
28412693	809	814	lipid	T109	C0023779
28412693	809	822	lipid -filled	T080	C4086317
28412693	823	834	giant cells	T025	C0016390
28412693	844	866	mesenteric lymph nodes	T023	C0229792
28412693	893	898	serum	T031	C0229671
28412693	899	906	amyloid	T116,T123	C0002716
28412693	911	922	haptoglobin	T116,T123	C0018595
28412693	939	946	ascites	T033	C0003962
28412693	952	959	survive	T052	C0038952
28412693	968	978	Angptl4-/-	T028	C1423931
28412693	979	983	mice	T015	C0206745
28412693	990	1010	saturated fatty acid	T168	C0597423
28412693	1017	1021	diet	T168	C0012155
28412693	1026	1046	RAW264.7 macrophages	T025	C0024432
28412693	1051	1081	saturated fatty acid palmitate	T109	C3503116
28412693	1101	1108	markers	T201	C0005516
28412693	1112	1124	inflammation	T046	C0021368
28412693	1133	1158	unfolded protein response	T043	C1155342
28412693	1172	1198	trans-unsaturated elaidate	T109	C3886672
28412693	1207	1229	cis-unsaturated oleate	T109,T121,T123	C0220884
28412693	1271	1276	trans	T109,T168	C1257879
28412693	1281	1302	saturated fatty acids	T168	C0597423
28412693	1322	1332	biological	T080	C0205460
28412693	1333	1340	effects	T080	C1280500
28412693	1355	1373	lipid accumulation	T033	C0333574
28412693	1377	1399	mesenteric lymph nodes	T023	C0229792
28412693	1418	1428	activation	T052	C1879547
28412693	1435	1455	acute-phase response	T046	C0001349
28412693	1460	1475	chylous ascites	T047	C0008732
28412693	1493	1500	ANGPTL4	T116,T123	C1438918
28412693	1545	1557	dyslipidemia	T047	C0242339